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Abstract 
Purpose. The objective of this work is to compare the behavior of two electroencephalogram 
(EEG) based indices after drug induction and during recovery of consciousness. 
Methods. Data was recorded from 140 patients scheduled for general anaesthesia with a 
combination of propofol and remifentanil. The qCON 2000 monitor (Quantium Medical, 
Barcelona, Spain) was used to calculate the qCON and qNOX. The fall times and the rise times 
were defined at the start and at the end of the surgery. Loss of response to verbal command and 
loss of eye-lash reflex were assessed during the transition from awake to anesthetized, defining 
the state of loss of consciousness (LOC). Movement as a response to laryngeal mask (LMA) 
insertion was interpreted as the response to the nociceptive stimuli. The patients were classified 
as movers or non-movers. The values of qCON and qNOX were statistically compared. 
Results. The qCON reached 65 in median (25th; 75th percentile) at 198.0 (114.0; 245.0) s after 
anaesthesia induction, while the qNOX fall time was significantly longer (p-value<0.05): 249.0 
(189.0; 322.0) s. At the end of the surgery, the qNOX started to increase to 85 at 5.0 (-44.0; 
46.0) s after recovery, while the qCON at 88.0 (-151.0; 40.0) s (p-value<0.05). The results show 
that the qCON has a predictive value of loss of consciousness such as loss of verbal command 
and eyelash reflex while the qNOX has a predictive value of response to noxious stimulation 
such as LMA insertion.  
Conclusion. The indices qCON and qNOX were able to detect differences between the times of 
actions of hypnotic and analgesic agents. The qCON showed faster decrease during induction 
while the qNOX showed a faster increase during recovery. 
Keywords: Anesthesia monitor, nociception, electroencephalography, clinical indexes. 
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Introduction. 
It remains a challenge whether the antinociception/nociception balance can be assessed as an 
individual component of depth of anaesthesia.  The hypnotic effect can be assessed by indices 
derived from the EEG, a number of different methods are available as experimental or 
commercial devices [1-6] whereas the assessment of nociception is less accepted due to the 
complexity and interpretation of the measurement.  
Several methods have been proposed to assess and quantitate the nociceptive response during 
general anesthesia [8-11] 
Autonomic nervous system measures, for example Heart Rate Variability (HRV) [12] or Skin 
Conductance (SC) [13] and parameters extracted, have been proposed and used by several 
authors. HRV and SC are correlated with sympathetic activity and therefore, monitors based on 
these parameters can measure the increase in sympathetic activity. However, increases in 
sympathetic activity can be caused by other factors not related to pain. Combinations of 
previous methods have also been described as potential indicators of nociceptive response as 
described by Schneider [14] or Ben-Israel [15]. Changes in pupil size [16, 17] or other HRV 
derived parameters studying parasympathetic activity [18] in response to opioid concentrations 
or noxious stimulation have also been proposed as methods to assess the level of analgesia in 
surgical patients.  
Predicted concentrations of drugs have also been used to define probability of response to a 
given stimulus as a function of the intensity of stimuli and the synergistic relation between 
propofol and opioids. The best studied is the Noxious Stimulation Response Index (NSRI)[19] 
which is an estimate of the interaction between predicted effect site concentrations (Ce) of 
propofol and remifentanil.  The NSRI is based on the hierarchical interaction model defined by 
Bouillon et al. in 2004[20]. The NSRI can be expressed as the probability to tolerate a certain 
reference stimulus for example tolerance of laryngoscopy. Recently, a new model of the NSRI 
has been developed to include the endtidal concentration of Sevoflurane as well [21]. The NSRI 
was also validated by von Dincklage [22], showing that the NSRI could predict movement (but 
not heart rate) responses to incision satisfactorily. 
The analysis of brain signals such as spontaneous EEG activity or the Auditory Evoked 
Potentials (AEP) have also been used. The main advantage is that they reflect the cortical 
response to anesthetic drug effects and noxious stimulation. The methods based on EEG 
analysis are typically empirical in their origin as there is no clear consensus of which frequency 
bands or features of the EEG correlate best to the antinociception/nociception balance during 
analgesia.  
Previous work from our group showed that the qNOX, a parameter extracted from the raw EEG 
using an adaptive neuro-fuzzy inference system (ANFIS), could predict the likelihood of 
movement response to different anesthetic and surgical stimuli [23]. ANFIS is a data driven 
modelling approach based on the principles of Fuzzy Logic.  
The objectives of the present study are to estimate the values of qCON, a biomarker of hypnotic 
effect under general anesthesia, and qNOX below which the loss of consciousness and loss of 
response to noxious stimulation are achieved and then to test the hypothesis that loss of 
consciousness occurs before loss of nociception by analyzing the fall and rise times for qCON 
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and qNOX at the beginning and at the end of the surgery. This can also contribute to deeper 
analyse the behaviour of the qCON and the qNOX as indexes of consciousness level and 
probability of response to noxious stimulation, during general anesthesia for surgical procedures 
as well as the response of both indexes in relation to changes of propofol and remifentanil effect 
site concentrations.   
Methods 
After IRB approval (Committee on Ethics in Research, Hospital CLINIC de Barcelona nº 
2013/8356) and written informed consent, data was recorded from 140 subjects. Patients were 
scheduled to receive general anaesthesia with a combination of propofol and remifentanil for 
different surgical procedures in the Ambulatory Surgery facility at Hospital CLINIC de 
Barcelona.  
 
General Anesthesia  
The TCI system (Base Primea, FreseniusKabi AG, Bad Homburg, Germany) administered 
propofol and remifentanil according to the predictions of pharmacokinetic and 
pharmacodynamic models.  In both cases the TCI was targeting the effect-site applying the 
Schnider model for propofol (Ce prop) [24,25] and the Minto model for remifentanil (Ce remi) 
[26,27]. Surgical procedures were ambulatory interventions including inguinal hernia repair, 
laparoscopic cholecystectomy, gynecologic laparoscopy and other gynecologic procedures. 
There were no specific requirements for anesthetic management with regards to preventing 
movement. Movements after stimuli were registered. 
The qCON and qNOX indices were continuously recorded. The data from the qCON and the 
qNOX indices were stored in a PC by means of proprietary software, qCON display (Quantium 
Medical, Spain). The qCON, qNOX, EMG, Burst Suppression and SQI (Signal Quality Index) 
were stored in a text file. Data with a SQI<50 were rejected. The data from the TCI system (Ce 
prop and Ce remi) were recorded with Rugloop (Demed, Belgium).  
 
Clinical end points. 
Loss of response to verbal command and loss of eye-lash reflex were assessed during the 
transition from awake to anesthetized, defining the state of loss of consciousness (LOC). The 
baseline values for the indices were the mean of the 1 min interval immediately before the TCI 
system was started while the anesthetized value was the mean taken over the 1 min interval 
immediately after LOC. Movement as a response to laryngeal mask (LMA) insertion was 
recorded. Movement in the period of one minute after applying the stimuli was interpreted as 
the response to the nociceptive stimuli. All relevant clinical endpoints were entered online as an 
event in Rugloop. The patients were classified as movers or non-movers and the mean value for 
the qCON and qNOX were calculated over the 1 min period after the stimulus.   
 
Speed of loss of consciousness and loss of response to noxious stimuli. 
In order to analyze the responses of the qCON and qNOX to the changes of hypnotic and 
analgesic concentrations and hence to assess the speed of loss of consciousness and loss of 
response to noxious stimuli, the fall and rise times of the two indices were defined at the 
beginning and at the end of the surgery. The fall times (Figure 4a) were defined as the 
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difference between the times when the effect site concentration of propofol or remifentanil was 
above zero (T0) and the time when qCON and qNOX reached a value below x (T <x) (Eq. 1-2). 
 
 Fall time qCON = T <x - T0                                                                              (1) 
Fall time qNOX = T <x - T0                                                                              (2) 
 
where T <x = min { t | qCON(t)<x  ˅	qNOX(t)<x  } and T 0 = min { t | Ce prop(t)>0  ˅	Ce 
remi(t)>0}, where t includes the time instants of the recorded qCON and qNOX of each patient. 
 
The rise times (Figure 4b) were defined as the difference between the time of recovery of 
consciousness (eye opening to verbal command) or response to noxious stimuli (TRC) and the 
times when qCON and qNOX reached a value above x (T>x) (Eq. 3-4). 
 
Rise time qCON = TRC - T >x                                                                             (3) 
Rise time qNOX = TRC -T >x                                                                             (4) 
where T >x = min { t  | t > T <x ˄	ሺ∀	t	⇾	qCON(t)>x  ˅ qNOX(t)>x )  } and T RC = min { t | t > T 
<x ˅ t = time when patients open eye or response to a noxious stimuli } 
 
 
Statistics. 
A power calculation was performed aiming at a power of 0.9 and a level of significance of 0.05.  
Previous experience showed that the SD of the qNOX is less than 20, and we considered a 
change of 10 units in response to noxious stimulation as significant, hence the standardized 
difference was 10/20 =0.5. According to Altman [28] with these conditions the necessary 
sample size is 140. 
The prediction probability, Pk [29], was used to assess the ability of the qCON and qNOX to 
predict the loss of consciousness and the responses to noxious stimulation. The Pk and its 
standard error (SE) were calculated using the jack-knife estimate which has the advantage that 
the variance can be estimated by the Student`s t distribution. To test for significance a Kruskal 
Wallis test was applied. The test was considered significant if p-value<0.05. 
Significant differences of the rise and fall times were tested using Mann Whitney U test and 
Wilcoxon signed-rank test. 
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Results 
A total of 140 patients were included and their data analyzed. There were 68 men and 72 
women, age 55 (17-88) years old, weight 70 (42-102) Kg. 
Figure 1 shows an example of time course of qCON and qNOX of a representative patient. 
Tables 1, 2 and 3 show the results of responses to verbal command, loss of eye-lash reflex and 
response to LMA insertion.  A Kruskal Wallis test was used to test for significance. There was a 
total of 165 noxious events where 146 were non responders and 19 were responders.  
Based on these results we consider the range between 65<qCON<85 for loss of consciousness 
(during non-steady state conditions such as induction) and 65<qNOX<85 as loss of response to 
noxious stimulation (placement of LMA). Hence, the limits of these ranges are used as x in 
equations 1-4, as it is shown in figure 2. 
 
Table 1. Loss of response to verbal command 
 qCON   qNOX   
 Mean SD Mean SD 
Response 92.98 9.93 95.18 9.21 
No response 67.72 17.88 88.25 13.42 
Pk(SE) 0.91 0.03 0.67 0.06 
P (Krus Wal) 0.00  0.01  
 
Table 2. Loss of response to eyelash reflex 
 qCON   qNOX   
 Mean SD Mean SD 
Response 91.93 10.89 94.81 9.45 
No response 58.27 16.80 79.93 19.22 
Pk(SE) 0.94 0.02 0.81 0.05 
P (Krus Wal) 0.00  0.00  
 
Table 3. Response to LMA insertion 
 qCON   qNOX   
 Mean SD Mean SD 
Response 59.07 15.91 78.45 27.00 
No response 47.88 12.99 59.02 20.23 
Pk(SE) 0.71 0.10 0.75 0.13 
p (Krus Wal) 0.06  0.03  
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Fig. 1 Example of the time course of qCON and qNOX of a representative patient. 
Table 4 shows that the qCON decreased below 85 at (median) 148.5 s  and below 65 at 183 s 
after anaesthesia induction, while the qNOX fall times were significantly longer (p-value<0.05). 
During recovery, the qNOX increased above 65 at (median) 57 s before recovery of 
consciousness and above 85 at  5 s after recovery of consciousness while the qCON increased to 
85 at 96 seconds after qNOX (p-value<0.05). 
Table 4. Fall and rise times for the qCON and qNOX. 
 qNOX Time (s) 
median (25th; 75th 
percentiles) 
qCON Time (s) 
median (25th ;   75th  
percentiles) 
qCON - qNOX Time (s) 
median (25th ; 75th 
percentiles) 
DECREASIN
G 
   
T<85 – T0 198.0 (114.0; 245.0)* 148.5 (67.0; 190.0) * - 24.0 (-64.0; -11.0) ** 
T<65  – T0 249.0 (189.0; 322.0) * 183.0 (122.0; 241.0) * -36.5 (-113.0; -18.0) ** 
INCREASING    
T>65 – TRC -57.0 (-171.0; 7.0) * -1.0 (-32.0; 60.0)* 22.0  (3.0;  122.0) ** 
T>85  – TRC 5.0 (-44.0; 46.0) * 88.0 (-151.0; -40.0) * 96.0 (26.0; 184.0) ** 
* p-value<0.005 U of Mann Whitney test; **p-value<0.005 Wilcoxon signed-rank test 
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(a)
 
(b) 
Fig. 2 Example of qCON and qNOX decreasing and increasing time calculation (a) after 
drug induction and (b) during recovery of consciousness 
Table 5 shows the values of the differences between the time of starting propofol (TProp) or 
remifentanil (TRemi) and the time values when qCON and qNOX decreased under 65.  The fall 
time calculated with respect to the TPropo is in general shorter than the fall time calculated with 
respect to the TRemi, for both qCON and qNOX. However, the qNOX showed a slower fall time 
(p-value<0.05) than qCON for both case of propofol and remifentanil. The averaged time 
differences between TRemi and TPropo resulted in a median of 97 (3; 125) seconds. In order to 
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study its influence on the results, the Pearson correlation between the time differences of 
starting of propofol and remifentanil and the differences between times when qCON and qNOX 
fallen under 65 (TRemi - TPropo versus qCON T<65 - qNOX T<65 )  was calculated and resulted equal 
to -0.0508. 
 
Table 5. Values of decreasing time of qCON and qNOX with respect to remifentanil and 
propofol.  
 qNOX Time (s) 
median (25th; 75th 
percentiles) 
qCON Time (s) 
median (25th ;   75th  
percentiles) 
DECREASING   
T<65 – TRemi 257.0 (194.0; 325.0)* 185.0 (133.0; 244.0) * 
T<65 – TPropo 164.5 (113.0; 238.0) * 92.5 (66.0; 141.0) * 
*p-value<0.005 Wilcoxon signed-rank test 
Pearson Correlation (TRemi - TPropo vs. qCON T<65 - qNOX T<65 ) = -0.0508 
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Discussion 
Based on the results of tables 1-3 it was possible to define the ranges for qCON and qNOX 
indicating loss of consciousness and loss of response to noxious stimulation, respectively. By 
using these values it was found that the qCON has a faster decrease than the qNOX after drug 
induction as shown in table 4. At the end of the recording, qNOX started to rise before the 
qCON (p-value<0.05). This implies that during recovery the probability of response to noxious 
stimuli assessed by the qNOX increases before the patient recovered consciousness, as assessed 
by the qCON. 
The results of Table 1 and 2, show that the mean value of the qCON at the moment of no 
response of verbal command and loss of eyelash reflex was already under 70, while the mean 
value of qNOX was yet higher than 75. 
Furthermore, observing the results in table 3, it can be deduced that during LMA insertion, the 
patients classified in the response group were already unconscious (mean value of the qCON 
below 60) but the mean value of qNOX was above 70. The clinical interpretation of all those 
results is that loss of consciousness is achieved before analgesia after anaesthesia induction. It 
also gives guidance to clinicians as how to control anesthetic effect by looking at qCON and 
qNOX as indicators of hypnosis and analgesia. 
The median time difference between TRemi and TPropo was 97 s, meaning that remifentanil was 
started 97 s before propofol (median). However, no correlation was found between the time 
differences of starting of propofol and remifentanil and the differences between times when 
qCON and qNOX had fallen below 65. In this way, it can be assumed that the differences 
between qCON and qNOX fall times were not influenced by the differences between the time of 
starting of propofol and remifentanil. Thus, the statistical differences between the fall times of 
the two indices can be only explained by the different features of qCON and qNOX that are able 
to assess unconsciousness and unresponsiveness, respectively. 
As shown in table 5, the fall times calculated with respect to the start of propofol infusion were 
shorter than the fall time calculated with respect to the remifentanil, for both qCON and qNOX. 
This means that the changes in EEG produced by remifentanil occurred later than the changes 
produced by propofol. Since qNOX showed higher fall times than qCON (p-value<0.05) in both 
cases, it can be assumed that qNOX is more accurate for detecting the analgesic effects induced 
in EEG. 
The results also show that the qCON has a predictive value of loss of consciousness such as loss 
of verbal command and eyelash reflex while the qNOX has a predictive value of response to 
noxious stimulation such as LMA insertion.  
The qCON had a lower Pk than the qNOX for prediction of LMA insertion (Table 3) whereas 
the opposite was the case for lighter stimuli and loss of response to verbal command (Table 1 
and 2).  Since loss of response to verbal command is an indicator of loss of consciousness, the 
Pk was higher for the qCON than the qNOX, while in case of response to nociceptive 
stimulation, the qNOX reached higher Pk than the qCON 
It is known that when using intravenous anesthetic drugs, the first order rate constant, ke0, and 
its corresponding half-time determine the pseudo-equilibration time between the concentration 
in plasma and the concentration at the effect site, the biophase concentration. From the 
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pharmacokinetics and the value of ke0it can be estimated the time course of drug effect including 
its onset and offset [30]. Considering the model of the present study, the ke0 of propofol was 
estimated to be 0.46 min-1 corresponding to a time of peak effect concentration of 1.7 min [25-
26]. Another study demonstrated that in the case of a single dose of propofol, peak effect 
concentration is obtained after about 4 min [31] while 80% of a final target concentration will 
be achieved at the effect site within about 6 min [32]. Wakeling et al. [33] found that a ke0 of 
0.63min-1 for propofol determined a loss of responsiveness in 1.23 min, and with a simulation 
they found that the desired effect site concentration was reached after 2 min. The present work 
shows consistent results with all these studies, obtaining a fall of the qCON under 65 between 2 
and 4 min after drug induction. Even though, it would be interesting to estimate the value of ke0 
optimized for qCON as it was done for BIS elsewhere [34]. 
 
The onset of remifentanil was studied by its half-time for equilibration between plasma and its 
effect compartment (t1/2 ke0 of 1.0–1.5 min) [35, 36]. This t1/2 ke0 resulted in a time to peak 
drug effect after a bolus of 1.5 min. 
 
Considering the effect on the EEG, the time to reach a steady-state concentration was 
demonstrated to be approximately 5 min to 70% of the final concentration or 10 min to 95% of 
the steady state [37]. These values are consistent with those observed for the fall time of the 
qNOX. In this way, since the qNOX showed higher fall times than qCON, it can be assumed 
that qNOX is more accurate for detecting the effects in EEG induced by opioid analgesic drugs. 
The plasma-effect site equilibration for BIS has been recently calculated to be approximately 
5.6 min [34]. However, there is evidence to suggest that BIS values do not reflect all 
components of anaesthesia [38], since opioids do not produce the basic anaesthesia-related EEG 
pattern. In general, opioids produce a dose-related decrease in frequency and increase in 
amplitude of the EEG. If further doses of opioids are not given, as with other drug, the opioid 
effect ceases and then alpha and beta activity will eventually return. The speed of return will 
depend on the drug itself and the amount given. Complete suppression of the EEG cannot be 
obtained with opioids and the potential interactive effect with hypnotics is an area worthy of 
further study. It is well known that indexes of consciousness such as qCON and BIS are 
designed to optimally correlate with the hypnotic effect on the EEG, while the results of this 
works suggest that qNOX index can better detect the changes in the EEG induced by the 
analgesic component. In this way, the use of a nociception index, associated with a hypnotic 
index, might help to indicate when an unresponsive state is reached with higher precision than 
when only a consciousness index is used.  
 
Considering the recovery of consciousness, qNOX showed a faster increase than qCON (p-
value<0.05). It can be deduced that the qNOX is able to detect quickly a change between 
unresponsive and responsive state compared with the qCON and it might help preventing pain 
during loss of consciousness. In a previous study [39], the mean time from the end of propofol 
and remifentanil infusions to 50% return of responsiveness is shown to be between 6 and 11 
min depending on the dose combination of the hypnotic and opioid. Another study 
demonstrated a rapid termination of remifentanil effect investigating the recovery from 
respiratory depression [40], in this way also its analgesic effect terminates rapidly. Observing 
the results of the present work, it is deduced that the end of the analgesic effect is described by 
the qNOX behavior during recovery of consciousness better than the qCON. 
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A limitation of this work is that the start time of infusion of propofol with respect to 
remifentanil is not the same for all the patients. In median, remifentanil infusion started 97 s 
before propofol, however in some case the start time differences was only 5 s and in a few cases 
propofol infusion started before remifentanil. In order to estimate and compare better the falling 
times of the two indexes, the same values of start time of propofol infusion with respect to 
remifentanil should be taken into account. However, no correlation (Pearson coefficient = -
0.0508) was found between the time differences of starting propofol and remifentanil and the 
differences between times when qCON and qNOX fallen under 65. In this way, the value of 
starting time of propofol with respect to remifentanil was not used as an exclusion criterion and 
it was possible to include in the study a high number of patients.  
To our knowledge this is the first study where the time of response to a change in the anesthetic 
state of both consciousness and nociception indexes were calculated and compared. Although 
the absence of a purposeful motor response has been traditionally used to determine anaesthetic 
potency [41] ,there is evidence to suggest that loss of consciousness and response to noxious 
stimuli are not consistent with a scale of increasing ‘depth’ of anesthesia but rather are two 
separate phenomena [42].  
 
From all the previous results, it can be deduced that the qNOX is able to quickly detect a change 
between unresponsive and responsive states compared with the qCON and it might avoid 
situations of pain during loss and recovery of consciousness.  The results of the present work 
confirm that the use of only a consciousness index is not enough in order to detect the effect of 
the analgesic induced in the EEG, and thus to monitor the responsiveness of the patients. 
 
Conclusion 
The qCON was able to predict loss of consciousness such as loss of verbal command and 
eyelash reflex while the qNOX was able to better predict response to noxious stimulation such 
as LMA insertion.  
The indexes qCON and qNOX were able to detect differences between the times of actions of 
hypnotic and analgesic agents.  The qCON showed faster decrease during induction while the 
qNOX showed a faster increase during recovery. This demonstrated that the probability of 
response to noxious stimuli increases before the patient recovered consciousness as assessed by 
the qCON. Hence the qNOX could be interpreted as an arousability index, indicating that the 
patient is likely to wake up. 
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